All In Biotech

Drug Trial Radar · NCT01623609

Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol

A Phase I, Randomised, Open-label, 3 Way Cross-over Study in Healthy Volunteers to Demonstrate the Bioequivalence of the Naloxegol 25 mg Commercial and Phase III Formulations and to Assess the Effect of Food Administration on the Pharmacokinetics of the Commercial Formulation.

Last checked: Nov 20, 2026Latest source record: Oct 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Jul 2012

Primary completion

Sep 2012

Study completion Sep 2012

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 20, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the Bioequivalence, assess food administration on the Pharmacokinetics with naloxegol.

Conditions

  • Opioid Induced Constipation

Interventions

  • NaloxegolDrug

    Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation

  • NaloxegolDrug

    Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Description of the pharmacokinetic (PK) profile for naloxegol in terms of maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC) for each treatment period.Time frame: Predose,0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 36, and 48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.